Myovant Sciences Ltd. Announces Pricing of $75.0 Million Public Offering of Common Shares
12 Jul 2018 at 12:00 pm ETPDF Version
BASEL, Switzerland, July 12, 2018 /PRNewswire/ — Myovant Sciences Ltd. (NYSE: MYOV) (“Myovant”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women’s health and endocrine diseases today announced the pricing of its underwritten public offering of 3,333,334 of its common shares at a price to the public of $22.50 per share. Gross proceeds to Myovant from the offering are expected to be approximately $75.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the common shares are being offered by Myovant. In connection with this offering, Myovant has granted the underwriters a 30-day option to purchase up to an additional 500,000 of its common shares on the same terms and conditions. The offering is expected to close on July 17, 2018, subject to customary closing conditions. Myovant currently intends to use the net proceeds from the offering primarily to fund its clinical development programs, preparations for the potential commercial launch of relugolix, as well as for working capital and other general corporate purposes.
J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Barclays Capital Inc. are acting as joint book-running managers for the offering. JMP Securities LLC and Robert W. Baird & Co. Incorporated are acting as co-managers.
A shelf registration statement relating to the offered common shares was filed with the Securities and Exchange Commission (SEC), and was declared effective on March 23, 2018. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website, located at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus related to the offering may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, by email at firstname.lastname@example.org or by phone at (866) 803-9204, Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, by email at Prospectusemail@example.com or by phone (866) 471-2526 and Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at Barclaysprospectus@broadridge.com or by phone at (888) 603-5847.
This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities, and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale is unlawful.
Myovant is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women’s health and endocrine diseases. Myovant’s goal is to be the leading global biopharmaceutical company focused on treating women’s health and endocrine diseases in areas of high unmet medical need.
This announcement contains forward-looking statements, including statements relating to Myovant’s expectations regarding the completion and timing of the proposed public offering, and use of proceeds. These statements are subject to significant risks and uncertainties; actual results could differ materially from those projected and Myovant cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering. There can be no assurance that Myovant will be able to complete the public offering on the anticipated terms, or at all. Risks and uncertainties relating to Myovant and its business can be found in the “Risk Factors” section of Myovant’s Form 10-K, filed with the SEC on June 7, 2018, and in the preliminary prospectus supplement related to the proposed offering filed with the SEC on July 11, 2018, and the final prospectus supplement related to the proposed offering to be filed with the SEC. Myovant undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in Myovant’s expectations.
Chief Financial Officer
View original content with multimedia:http://www.prnewswire.com/news-releases/myovant-sciences-ltd-announces-pricing-of-75-0-million-public-offering-of-common-shares-300680553.html
SOURCE Myovant Sciences